205 related articles for article (PubMed ID: 30362917)
1. Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States.
Wu CF; Xu L; Fu S; Peng HL; Messick CA; Lairson DR
J Manag Care Spec Pharm; 2018 Nov; 24(11):1156-1164. PubMed ID: 30362917
[TBL] [Abstract][Full Text] [Related]
2. Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas.
Fu S; Lairson DR; Chan W; Wu CF; Ramondetta L
Gynecol Oncol; 2018 Feb; 148(2):342-348. PubMed ID: 29274828
[TBL] [Abstract][Full Text] [Related]
3. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas.
Lairson DR; Fu S; Chan W; Xu L; Shelal Z; Ramondetta L
Gynecol Oncol; 2017 Apr; 145(1):108-113. PubMed ID: 28196673
[TBL] [Abstract][Full Text] [Related]
4. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
6. Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States.
Lairson DR; Wu CF; Chan W; Fu S; Hoffman KE; Pettaway CA
Urol Oncol; 2019 Apr; 37(4):294.e17-294.e25. PubMed ID: 30660492
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic burden of HPV-related cancers in the US veteran population.
Saxena K; Dawson RS; Cyhaniuk A; Bello T; Janjan N
J Med Econ; 2022; 25(1):299-308. PubMed ID: 35156867
[TBL] [Abstract][Full Text] [Related]
8. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Study of HPV Vaccination as a Primary Prevention Strategy for Anal Cancer in HIV-Positive Men in Chile.
Vargas Parada C; Lennert Veerman J
Value Health Reg Issues; 2016 Dec; 11():17-23. PubMed ID: 27986194
[TBL] [Abstract][Full Text] [Related]
11. Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States.
Prabhu V; Kathe N; Saxena K; Walia A; Markan R; Myers E; Einstein M
Curr Med Res Opin; 2021 Sep; 37(9):1599-1607. PubMed ID: 34018457
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
15. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
Kim JJ
Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
[TBL] [Abstract][Full Text] [Related]
16. Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017.
Liao CI; Francoeur AA; Kapp DS; Caesar MAP; Huh WK; Chan JK
JAMA Netw Open; 2022 Mar; 5(3):e222530. PubMed ID: 35294540
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis.
Chin L; Hansen RN; Carlson JJ
J Manag Care Spec Pharm; 2020 Aug; 26(8):962-970. PubMed ID: 32715961
[TBL] [Abstract][Full Text] [Related]
18. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany.
Heitland W; Schädlich PK; Chen X; Rémy V; Moro L
J Med Econ; 2013; 16(3):364-71. PubMed ID: 23253056
[TBL] [Abstract][Full Text] [Related]
19. Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas.
Zhao B; Fu S; Wu CF; Dahlstrom KR; Fokom Domgue J; Tam S; Xu L; Sturgis EM; Lairson DR
Oral Oncol; 2019 Sep; 96():21-26. PubMed ID: 31422209
[TBL] [Abstract][Full Text] [Related]
20. Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States.
Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
Hum Vaccin Immunother; 2019; 15(7-8):1942-1948. PubMed ID: 31107640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
